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Alpha-synucleinopathies, such as Parkinson’s disease (PD), dementia with Lewy bodies
(DLB), and multiple system atrophy (MSA), are a class of neurodegenerative diseases.
A diagnosis may be challenging because clinical symptoms partially overlap, and there
is currently no reliable diagnostic test available. Therefore, we aimed to identify a suitable
marker protein in cerebrospinal fluid (CSF) to distinguish either between different types of
alpha-synucleinopathies or between alpha-synucleinopathies and controls. In this study,
the regulation of different marker protein candidates, such as alpha-synuclein (a-Syn),
neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and total tau (tau) in
different types of alpha-synucleinopathies, had been analyzed by using an ultrasensitive
test system called single-molecule array (SIMOA). Interestingly, we observed that CSF-
NfL was significantly elevated in patients with DLB and MSA compared to patients with
PD or control donors. To differentiate between groups, receiver operating characteristic
(ROC) curve analysis resulted in a very good diagnostic accuracy as indicated by the
area under the curve (AUC) values of 0.87–0.92 for CSF-NfL. Furthermore, we observed
that GFAP and tau were slightly increased either in DLB or MSA, while a-Syn levels
remained unregulated. Our study suggests NfL as a promising marker to discriminate
between different types of alpha-synucleinopathies or between DLB/MSA and controls.
Keywords: alpha-synucleinopathies, biomarker, neurofilament light chain, SIMOA assay, cerebrospinal fluid
INTRODUCTION
Alpha-synucleinopathies are a group of neurological disorders, including Parkinson’s disease (PD),
dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). They share common
overriding symptoms such as rigidity, rest tremor, akinesia, autonomic, behavioral, cognitive-motor
dysfunctions like freezing, and speech problems (Kompoliti and Metman, 2010). PD is the common
Abbreviations: a-Syn, alpha-synuclein; AUC, area under the curve; CSF, cerebrospinal fluid, GFAP, glial fibrillary acidic
protein; DLB, dementia with Lewy bodies; LB, Lewy bodies; MSA, multiple system atrophy; NfL, neurofilament light chain;
PD, Parkinson’s disease; ROC, receiver operating characteristic; SIMOA, single-molecule array; tau, total tau.
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subgroup of synucleinopathies with a 1.6% of incidence rate
among people over 65 years of age (De Rijk et al., 1997).
The prevalence of synucleinopathies is around 21 per 100,000
person-years, and it increases excessively with age (Savica
et al., 2013). The patients with PD show clinical symptoms
when approximately 50% of substantia nigra cells and striatal
dopamine are lost and patients with DLB experience visual
hallucinations, cognitive impairments, and conscious problems
(Kompoliti and Metman, 2010).
Alpha synucleinopathies are mainly characterized by alpha-
synuclein (a-Syn) aggregates in the brain tissue. While PD and
DLB possess the formation of Lewy bodies (LB) in neurons
(Spillantini et al., 1997), MSA is characterized by glial cytoplasmic
inclusions (GCIs) in non-neuronal cells, i.e., oligodendrocytes
(Wakabayashi et al., 1998).
The misdiagnosis of alpha-synucleinopathies may occur due
to a clinical overlap of symptoms and the lack of specific
diagnostic tests or biomarkers. A confirmed diagnosis
requires postmortem examination by autopsy, which
confirms approximately 80% of premortal clinical diagnoses
(Savica et al., 2013).
Until present, the colorimetric ELISA system and western
blotting are commonly used for protein analysis in a diagnostic
context. However, small changes in the protein concentration
cannot be detected effectively by these standard methods for
protein analyses. The high technological progress of protein
analytics had been achieved by the development of the digital
ELISA concept, such as the ultrasensitive single-molecule array
(SIMOA) (Rissin et al., 2010). SIMOA measures proteins in
femtomolar (fM) concentrations (Rissin et al., 2010) and can
detect minuscule changes in protein concentrations related to the
pathological processes in the brain, which were not measurable by
the standard analog methods. These alterations may be important
for diagnostic and understanding of neuropathological processes.
In this study, we analyzed the concentration of potential
marker protein candidates, such as neurofilament light chain
(NfL), glial fibrillary acidic protein (GFAP), a-Syn, and total tau
(tau) in patients with different types of alpha-synucleinopathies.
Diagnostic accuracies were estimated by the receiver operating
characteristic (ROC) curve analysis.
METHODS
Patients
This study includes patients with alpha-synucleinopathies that
were classified as PD (Postuma et al., 2015), DLB [criteria
based on the McKeith criteria (McKeith et al., 2017)], and MSA
(criteria based on the Gilman criteria) (Gilman et al., 1999, 2008);
autopsies were not available (Table 1).
The control group was composed of cases diagnosed with
non-primary neurodegenerative neurological and psychiatric
conditions according to the acknowledged standard neurological,
clinical, and para-clinical findings based on the ICD-10
definition cases, without cognitive impairment or dementia
at the time of sampling. The number of patients in each
group can be noted in the corresponding part in Table 1.
Blood-contaminated cerebrospinal fluid (CSF) samples were
excluded from the study.
Sample Pretreatment
All protein concentrations were measured with the SIMOA-
SR-X machine (Quanterix, Billerica, MA, United States). We
have used commercial assay kits from Quanterix. All assays
have already been optimized for certain marker proteins. In this
study, we followed the protocols provided by Quanterix and
applied the recommended reaction conditions to obtain the most
accurate outcome. In addition, each assay contains two internal
controls with a defined protein concentration. Only when both
internal assay controls were in the expected range (less than 10%
variation), we subjected the data for further analysis.
Kits and samples were brought to room temperature before
pipetting. CSF samples were vortexed for 10–20 s and centrifuged
for 5 min at 10,000 rpm to remove impurities before use.
Initially, we analyzed each sample in duplicates and observed
that the intra-assay variation was marginal and not statistically
significant (Supplementary Figures 1A,B). Later, we proceeded
with single measurements due to low sample volumes. All
samples had an identification code and were analyzed blinded
and randomly by the experimenter.
Determination of NfL
The CSF samples were diluted at 1:100 to a total volume of
100 µl. Capture antibody-coated beads (25 µl) and biotin-
labeled detector antibodies (20 µl) were pipetted to the wells.
Subsequently, the plate was incubated on an orbital shaker for
30 min at 30◦C at 800 rpm using a black covering lid for
protection from light. After washing, 100 µl of streptavidin
β-galactosidase (SβG) was added to the wells, and the plates were
incubated for 10 min at 30◦C. After a couple of washing steps, the
plate was placed in the SR-X machine for measurements.
Determination of Tau
For tau measurements, the reaction volume was 152 µl per well.
We applied the same protocol mentioned before. The dilution
of CSF was 1:10. Bead and detector antibody solutions were
pipetted, and the plate was incubated at 35◦C at 800 rpm for
20 min on an orbital shaker. The SβG solution was prepared
by mixing diluent and reagent according to the described
proportion. After incubation and washing, SβG solution was
added to the samples and incubated for 10 min. After several steps
of washing, the plate was placed on the machine for analysis using
the tau protocol.
Determination of GFAP
We have followed the recommended dilutions according to
the protocol of the manufacturer. CSF samples were diluted
1:40. Calibrators were prepared following the protocol on kit
instructions. Bead solution was prepared from bead stock after
washing and diluting in bead diluent. Detector reagent was also
prepared according to the recommendation of the manufacturer.
SβG stock solution (10 nM) was diluted to 0.150 nM. Bead
(25 µl) and detector (20 µl) antibody solutions were pipetted
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TABLE 1 | Summary of the demographic information about patients and biomarker concentration.
DLB MSA PD Controls
NfL Number of Individuals (F/M) 23 (7:16) 26 (14:12) 29 (9:20) 35 (10:22)*
Age ± S.D. 71.17 ± 10.13 65.15 ± 11.12 66.38 ± 11.44 60.75 ± 13.39
Meant ± S.E.M (pg/mL) 2,190.76 ± 421.46 3,839.32 ± 615.85 960.55 ± 108.82 810.00 ± 104.81
GFAP Number of Individuals (F/M) 27 (10:17) 26 (14:12) 32 (10:22) 28 (10:15)*
Age ± S.D. 72.03 ± 9.55 65.15 ± 12.66 65.56 ± 10.36 62.32 ± 13.49
Meant S.E.M (pg/mL) 9,451.86 ± 1,669.36 10,291.36 ± 1,736.94 4,938.28 ± 853.62 7,693.76 ± 839.87
a-Syn Number of Individuals (F/M) 18 (5:13) 26 (14:12) 31 (9:22) 35 (11:20)*
Age ± S.D. 72.61 ± 9.81 65.15 ± 12.66 65.97 ± 11.01 61.06 ± 13.76
Meant S.E.M (pg/mL) 1,468.6 ± 350.69 1,532.30 ± 336.40 1,544.61 ± 249.51 1,299.91 ± 111.32
Total Tau Number of Individuals (F/M) 20 (6:14) 27 (14:13) 25 (9:16) 21 (5:13)*
Age ± S.D. 71.5 ± 10.64 65.07 ± 12.43 68.32 ± 9.11 62.28 ± 12.67
Meant S.E.M (pg/mL) 140.36 ± 27.79 80.01 ± 7.16 62.53 ± 6.21 95.51 ± 10.40
*The rest is unknown.
to the wells and incubated on an orbital shaker for 30 min at
30◦C with shaking at 800 rpm. After washing, 100 µl of SβG
solution were pipetted to wells and incubated again at the same
condition for 10 min. After SβG treatment we followed the GFAP
analysis protocol.
Determination of a-Syn
All CSF samples were diluted at 1:10 in sample dilution buffer.
The preparation of bead and detector solutions was performed
as described in the “Determination of GFAP” section. SβG
solution was to a final concentration of 0.075 nM as the final
concentration. All solutions were pipetted in the same order and
the same amount as in GFAP measurement and incubated at
35◦C for 35 min on an orbital shaker with shaking at 800 rpm.
After washing and SβG addition, the plate was incubated for
10 min at the same condition, then the plate was transferred to the
SR-X machine, and protocol for a-Syn analysis was performed.
Statistical Analysis
The normality of values was investigated by the Dallal–
Wilkinson–Lille test. For multiple comparisons, we performed
non-parametric testing by the Kruskal–Wallis one-way analysis
with Dunn’s test for post hoc comparisons. The ROC curves
were calculated, and the area under the curve (AUC) values
were extracted by using the software GraphPad Prism 6.0.1 (San
Diego, CA, United States). All correlation studies were computed
by using the non-parametric Spearman’s correlation test (two-
tailed) with a CI of 95%. The p-values below 0.05 are considered
statistically significant.
Ethical Issues
The study was conducted according to the revised Declaration
of Helsinki and Good Clinical Practice guidelines and
has been approved by the Local Ethics Committee of the
University Medicine Göttingen, No. 19/11/09 “Liquormarker als
Prädiktoren für die Entwicklung einer Demenz bei Patienten mit
Morbus Parkinson, Demenz mit Lewy Körperchen und Morbus
Alzheimer” and by the Ethics Committee of the University
Medicine Göttingen, No. 13/11/12 “LIX – Liquormarker zur
Frühdiagnose und Krankheitsprogression bei Patienten mit
Parkinson-syndromen und Motoneuronerkrankungen.”
RESULTS
Determination of NfL-, GFAP-, Tau-, and
a-Syn Levels in the CSF of Patients With
Alpha-Synucleinopathy
The CSF samples from different subgroups of alpha-
synucleinopathies (i.e., PD, DLB, and MSA) were subjected
to the SIMOA analysis. The levels of four protein marker
candidates, namely, NfL, GFAP, tau, and a-Syn, were measured
by commercially available assay kits from Quanterix, following
either a two- or a three-step protocol.
Our measurements indicated a significant increase in the NfL
levels in patients with MSA compared to those with PD and
controls (p < 0.001). In addition, patients with DLB exhibited
higher NfL concentrations than patients with PD as well as
control individuals (p < 0.001) (Figure 1A and Table 1).
A second neurodegenerative CSF-marker, tau, was moderately
increased in patients with DLB compared to those with PD and
the control group (p < 0.05) (Figure 1B).
When we compared CSF-GFAP levels in different types of
alpha-synucleinopathies, our obtained data indicated elevated
GFAP levels in patients with MSA compared with PD (p < 0.05)
(Figure 1C). In the remaining groups, CSF-GFAP levels were not
significantly regulated (Figure 1C).
The levels of a-Syn, the common causative player of all
synucleinopathies, were not significantly changed between all
groups and it did not correlate with age (Figure 1D and
Supplementary Figures 2A–C).
Determination of Diagnostic Accuracy of
NfL to Discriminate Patients With DLB
and MSA From Patients With PD and
Controls
To determine the diagnostic accuracy of CSF-NfL, we conducted
the ROC curve analyses using the software GraphPad Prism 6.0.1.
Frontiers in Aging Neuroscience | www.frontiersin.org 3 September 2021 | Volume 13 | Article 717930
fnagi-13-717930 September 21, 2021 Time: 10:58 # 4
Canaslan et al. Detection of NfL in Alpha-Synucleinopathies
FIGURE 1 | Detection of neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), alpha-synuclein (a-Syn), and tau levels in cerebrospinal fluid (CSF).
Potential marker candidate proteins were determined in CSF of synucleinopathy patients with Parkinson’s disease (PD), dementia with Lewy bodies (DLB), multiple
system atrophy (MSA), and controls (C). (A) The NfL levels were increased in patients with both MSA and DLB compared with PD and controls. (B) The tau levels
were higher in patients with DLB than those with PD. (C) The GFAP levels were higher in patients with MSA than those with PD. (D) No significant changes in a-Syn
concentrations were observed between groups. The values displayed are means and SDs. A ***p-value < 0.001 is considered as extremely significant, *p < 0.05 as
significant, and p ≥ 0.05 as not significant.
FIGURE 2 | Receiver operating characteristic (ROC) curve analysis of CSF-NfL levels. To increase the statistical power, we combined DLB and MSA in one group
considered as other synucleinopathies. (A) The diagnostic accuracy of CSF-NfL was assessed with ROC-derived area under the curve (AUC) values (with 95% CI)
for the discrimination of patients with other alpha-synucleinopathies from PD. The AUC values of 0.87 ± 0.04 SD, 95% CI of 0.79–0.95 indicated a very good
diagnostic accuracy. (B) The diagnostic accuracy of CSF-NfL was assessed for the discrimination of patients with other alpha-synucleinopathies from controls
(indicated as C). The AUC values of 0.92 ± 0.03 SD, 95% CI of 0.87–0.98 indicated a very good diagnostic accuracy.
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We combined MSA and DLB to increase the statistical power.
Interestingly, the ROC curve analysis indicated an AUC value
of 0.87 to differentiate between DLB/MSA and PD (p < 0.0001)
(Figure 2A). To distinguish between other synucleinopathy
group and controls, our analysis revealed an AUC value of 0.92
(p < 0.0001) (Figure 2B). Both ROC curve analyses suggested
CSF-NfL as a suitable marker to discriminate between other
synucleinopathies and classical PD as well as between other
synucleinopathies and controls.
Subsequently, we stratified the other synucleinopathy group
in MSA and DLB. The ROC curve analysis indicated that CSF-
NfL differentiated MSA from PD and control cases with a very
good diagnostic accuracy. The AUC values were between 0.90
and 0.96, respectively (Figures 3A,B). In contrast, the ROC
curve analysis produced a lower accuracy, when we assessed the
diagnostic accuracy of CSF-NfL for differentiating DLB from
PD and controls, indicated by the AUC values of 0.78 and 0.88
(Figures 3C,D).
DISCUSSION
With populations growing and aging worldwide, the
development of novel and less-invasive diagnostic test
systems has become an urgent need. Currently, the diagnostic
application of certain biomarkers in body fluids of patients
FIGURE 3 | Receiver operating characteristic curve analysis of CSF-NfL levels from patients with MSA and DLB. ROC analyses were performed with the CSF-NfL
concentrations obtained for the different diagnostic groups. (A,B) The diagnostic accuracy of CSF-NfL was assessed with ROC-derived AUC values (with 95% CI) for
the discrimination of patients with MSA from PD and controls. The AUC values of 0.90 ± 0.04 SD, 95% CI of 0.82–0.98 and 0.96 ± 0.02 SD, 95% CI of 0.91–1.00
indicated a very good diagnostic accuracy. (C,D) The diagnostic accuracy of CSF-NfL was assessed for the discrimination of patients with DLB from PD and
controls (indicated as C). The AUC values of 0.78 ± 0.07 SD, 95% CI of 0.65–0.91 and 0.88 ± 0.04 SD, 95% CI of 0.79–0.97 indicated a good diagnostic accuracy.
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with alpha-synucleinopathies is still a matter of debate
(Eller and Williams, 2011; Schade and Mollenhauer, 2014).
Therefore, our aim is to analyze the expression of potential
protein marker candidates in CSF to identify a suitable
marker to differentiate either between different subgroups of
alpha-synucleinopathies or between other synucleinopathies
and controls without neurodegeneration. We have selected
four promising marker protein candidates, namely, NfL,
a-Syn, tau, and GFAP, to cover a certain spectrum of
neurodegeneration to inflammation. Applying a novel
technology, based on SIMOA, allows us an ultrasensitive
detection of these four proteins to describe potential subtle
differences between groups.
CSF-NfL as an Accurate Marker to
Differentiate Between DLB/MSA and PD
or Controls
In neurodegenerative diseases, CSF is a valuable source for
biomarkers because it reflects neurodegenerative processes in the
brain (Cramm et al., 2015, 2016; Schmitz et al., 2016a,b; Zerr
et al., 2019; Llorens et al., 2020). When we determined CSF-NfL, a
known marker for several neurodegenerative diseases, reflecting
the neuroaxonal damage (Holmberg et al., 1998; Petzold, 2005),
we obtained a highly significant increase of NfL levels in patients
with DLB and MSA compared to those with PD and controls.
The ROC curve analyses suggested an accurate diagnostic
accuracy of CSF-NfL to differentiate either between other
synucleinopathies (i.e., DLB and MSA) from PD as indicated by
an AUC value of 0.87 or between other synucleinopathies and
controls as indicated by an AUC value of 0.92.
Previous studies on NfL detection in alpha-synucleinopathies
already observed the elevated NfL levels in CSF of patients
with MSA and DLB (Holmberg et al., 1998; Abdo et al.,
2007). The diagnostic accuracy of CSF-NfL to differentiate
MSA from PD was indicated by the AUC values of about
0.85–0.90 (Abdo et al., 2007; Hall et al., 2012; Magdalinou
et al., 2015), which is in line with our observations. Potential
differences between studies may depend on the composition
of the patient cohort or the kind of methodology used for
the measurement.
Regulation of Other CSF Biomarkers in
Alpha-Synucleinopathies
In addition, we analyzed the regulation of other potential
biomarker candidate proteins in CSF by using assays based
on the SIMOA technology. We observed a moderate tau
upregulated in CSF of DLB compared to PD cases. Since we
have measured tau and not the phosphorylated forms of tau
in PD and DLB, which might give further information about a
potential implication of tau, the diagnostic relevance of tau in
synucleinopathies is limited.
The upregulation of CSF-tau in DLB is in line with our
previous study (Llorens et al., 2016) using a colorimetric
detection system and others (Mollenhauer et al., 2011;
Mondello et al., 2014).
In addition, we observed GFAP [a type III intermediate
filament and the key component of the astrocyte cytoskeleton
(Eng et al., 2000; Yang and Wang, 2015)] upregulated in patients
with MSA. CSF-GFAP, mainly expressed in fibrillary astrocytes,
was already described to be slightly upregulated in DLB, a
distinct type of other synucleinopathies, compared with controls
(Ishiki et al., 2016).
We observed no significant alterations of CSF-a-Syn levels
between different diagnostic groups. Previous studies using a
colorimetric a-Syn assay or an assay based on the Mesoscale
technology revealed a moderated decrease of CSF-a-Syn in
alpha-synucleinopathies compared with controls. No significant
regulation was reported between different subgroups of
synucleinopathies, such as PD, DLB, and MSA, which is in line
with our current study (Llorens et al., 2017; Schmitz et al., 2019).
The strength of our study is that we applied the novel
and ultrasensitive SIMOA to measure potential CSF protein
marker candidates for alpha-synucleinopathies. The assays are
commercially available and well-validated. In future studies,
we also plan to develop a Homebrew assay for the detection
of epigenetically modified a-Syn or tau species, such as
different phosphorylated forms. A limitation of this analysis
is the low number of available DLB cases that impeded
a proper calculation of diagnostic accuracy. Therefore, a
confirmation of our observations in larger cohorts or with
alternative methodologies (e.g., analog or multiplexing detection
systems) is suggested.
CONCLUSION
Our study applied an innovative digital methodology (i.e.,
SIMOA), which enabled us to detect even subtle regulations
in CSF, suggesting NfL as a potential diagnostic marker for a
reliable discrimination either between other synucleinopathies
(i.e., DLB and MSA) and PD or between other synucleinopathies
and controls. This is of particular interest because, in the
daily clinical routine, it is more difficult to differentiate the
PD-type of MSA (MSA-P) and PD than to differentiate
MSA and DLB. Therefore, NfL may become important as a
marker to identify those patients, allowing to include them
in disease-modifying trials early in the disease course and
to inform them about the quite different prognosis and
characteristics of MSA disease.
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Supplementary Figure 1 | Analysis of intra-assay variations of NfL in CSF. We
chose different concentrations (high and low) to compare pairwise the NfL levels
measured in duplicates on the same plate (A). Statistical analysis revealed no
significant (ns) between both measurements (B), p > 0.05.
Supplementary Figure 2 | Analysis of a potential correlation between a-Syn
levels and age. (A–C) In synucleinopathy patients and controls, we correlated
aSyn levels and age. No correlation was detected between all groups. All
correlation studies were computed by using the non-parametric Spearman’s
correlation test (two-tailed) in a CI of 95%. A ∗p-value < 0.05 was considered as
significant and p ≥ 0.05 as not significant.
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